Oncgnostics
Oncgnostics GmbH, a Jena, Germany-based cancer diagnostics company, develops the Gyntect in-vitro diagnostic test for cervical cancer screening. It serves healthcare providers through international distribution partners, with the test commercialized in China and expanding into ASEAN markets.
- Company typePrivate
- Founded2013
- HeadquartersJena, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oncgnostics does
Oncgnostics GmbH is a Jena, Germany-based in-vitro diagnostics (IVD) company developing molecular cancer diagnostic tests for screening, therapeutic decision-making, and follow-up care. Its primary commercial product is Gyntect, a proprietary cervical cancer detection test positioned as differentiated on accuracy and precision. Founded in 2012 with seed support from German public and regional investors (HTGF and STIFT Thuringen), the company has remained operationally compact at 1-10 employees and continues to derive substantially all of its commercial activity from a single product line; specific underlying technology platform details — such as biomarker chemistry or assay methodology — are not disclosed in available sources.
The commercial model centers on partner-led distribution rather than direct sales. Following regulatory approval and a successful commercial launch of Gyntect in China, Oncgnostics is pursuing geographic expansion into ASEAN countries under a relationship with Hong Kong-based Grande Bio-tech Co. Ltd., which invested €7M in the company in September 2023 and concurrently acts as the channel partner. End customers are healthcare providers performing cervical cancer screening; the company has not publicly disclosed pricing, customer logos, hospital networks, or revenue split by segment, making third-party verification of commercial traction impossible from the available data.
Revenue is not disclosed. Funding across three documented rounds consists of a 2012 seed round (HTGF, STIFT Thuringen), a 2015 Series 2 (HTGF, STIFT Thuringen, bm-t beteiligungsmanagement thuringen, ITAI GmbH, Sparkasse Jena), and the 2023 €7M corporate round from Grande Bio-tech. The company is founder-led, with Alfred Hansel as CEO, Martina Schmitz as CSO, and co-founders Kerstin Brox and Matthias Durst; Peter Haug serves as Founding Angel and Head of Business Development and Licensing, indicating a founder/angel ownership structure without disclosed institutional majority shareholders.
Oncgnostics firmographics
Firmographics- Name
- Oncgnostics
- Legal name
- Oncgnostics GmbH
- Website
- https://oncgnostics.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Oncgnostics GmbH, a Jena, Germany-based cancer diagnostics company, develops the Gyntect in-vitro diagnostic test for cervical cancer screening. It serves healthcare providers through international distribution partners, with the test commercialized in China and expanding into ASEAN markets.
- Ownership category
- akta.pro rank
Where Oncgnostics is headquartered
LocationHeadquarters
- HQ city
- Jena
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Oncgnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Diagnostic Test Sales: Revenue generated from the sale of the Gyntect cervical cancer detection test. The test has been approved and launched in China with expansion planned for ASEAN markets.
Go-to-market motion1 record
Distribution channels1 record
Oncgnostics product offering
Product offeringCore offering
Oncgnostics develops and commercializes in-vitro diagnostic (IVD) tests for cancer screening, therapeutic decision-making, and follow-up care. Its flagship product, the Gyntect cervical cancer detection test, has been approved and launched in China, with distribution being expanded into ASEAN markets through channel partnerships.
Product overview
Oncgnostics offers a single diagnostic product, the Gyntect cervical cancer detection test. The company is focused on expanding the geographic distribution of this test from its established presence in China into Southeast Asian markets.
Differentiator
Problem solved
Functional benefit
Brands
- Gyntect: Cervical cancer detection test developed by Oncgnostics
Products and services
- Gyntect A molecular cervical cancer detection test (IVD) that identifies cervical cancer at early, more treatable stages; designed for use by healthcare providers, laboratories, and cervical cancer screening programs. The test has been approved and commercially launched in China with ongoing distribution expansion into ASEAN markets.
Quantifiable outcome
- Successful launch of Gyntect cervical cancer test in China following regulatory approval
Companies that use Oncgnostics
Customer profileSegments1 record
Ideal customer profiles1 record
Oncgnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Oncgnostics partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
Oncgnostics competitors and assessment
Company assessmentDirect peers
- Seegene: Korea-based molecular diagnostics company specializing in multiplex PCR IVD tests, including HPV and women's health panels. Closely comparable to Oncgnostics in technology (molecular IVD), target customers (clinical labs, screening programs), and Asia-centric commercial focus.
- Epigenomics (Novigenix): Germany-based molecular diagnostics company developing blood-based cancer detection tests using DNA methylation biomarkers. Direct peer in technology approach (methylation-based IVD), indication class (cancer diagnostics), and geographic base (Germany).
Broad incumbents
- Roche Diagnostics: Operates the cobas HPV test, one of the leading molecular cervical cancer screening assays globally. Direct competitor in primary HPV-based and reflex cervical cancer testing workflows.
- BD (Becton Dickinson): Provides cervical cancer screening solutions (BD Onclarity HPV assay) and broader women's health diagnostics. Comparable in cervical cancer screening indication and IVD product category, though within a much larger diversified portfolio.
- Qiagen: Global molecular diagnostics leader with HPV and cervical cancer screening products (e.g., careHPV, digene HC2). Directly comparable to Oncgnostics in target indication (cervical cancer) and IVD technology class, but operates at vastly greater scale and portfolio breadth.
- Hologic: Diagnostics company with a dominant cervical cancer screening franchise (ThinPrep Pap, Aptima HPV). Competes head-to-head with Oncgnostics in cervical cancer screening and represents the established standard of care Oncgnostics must displace or complement.
- Cepheid (Danaher): Molecular diagnostics player with the GeneXpert platform, used for HPV and women's health testing. Comparable in molecular IVD technology class and clinical lab customer base, though with broader infectious disease and oncology menus.
Emerging players
- DiaCarta: Molecular diagnostics company developing cancer and infectious disease IVD tests, with a focus on China and other Asia-Pacific markets. Comparable in size profile, molecular IVD focus, and APAC commercial orientation.
- GeneFirst: UK-based molecular diagnostics company focused on multiplex IVD assays, including in women's health and oncology. Comparable as a smaller molecular IVD player targeting similar clinical lab customers, with a complementary product portfolio.
Regional players
- Abogen Biosciences: China-based molecular diagnostics company with HPV and infectious disease IVD tests, including HPV genotyping products used in cervical cancer screening. Highly relevant as a regional competitor sharing the same Chinese market entry Oncgnostics has achieved.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Oncgnostics social profiles
Digital presenceOncgnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncgnostics leadership team
Management profileNumber of profiles
Profiles1 record
Oncgnostics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncgnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncgnostics
What does Oncgnostics do?
Oncgnostics develops and commercializes in-vitro diagnostic (IVD) tests for cancer screening, therapeutic decision-making, and follow-up care. Its flagship product, the Gyntect cervical cancer detection test, has been approved and launched in China, with distribution being expanded into ASEAN markets through channel partnerships.
Is Oncgnostics a public or private company?
Oncgnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Oncgnostics founded?
Oncgnostics was founded in 2013. It employs 1 to 10 people.
Where is Oncgnostics based?
Oncgnostics is headquartered in Jena, Germany, in the Europe region.
How does Oncgnostics make money?
One revenue line is on record: diagnostic Test Sales.
Who are Oncgnostics's main competitors?
Direct peers on record are Seegene and Epigenomics (Novigenix). Broad incumbents are Roche Diagnostics, BD (Becton Dickinson), Qiagen, Hologic and Cepheid (Danaher). Emerging players are DiaCarta and GeneFirst. Abogen Biosciences is listed as a regional player.
Does Oncgnostics have an API?
No public API is recorded for Oncgnostics.